- Type / Class
- Equity / Common Stock
- Shares outstanding
- 82,201,196
- Total 13F shares
- 83,462,300
- Share change
- +12,902,507
- Total reported value
- $1,524,931,940
- Put/Call ratio
- 30%
- Price per share
- $18.27
- Number of holders
- 164
- Value change
- +$249,855,302
- Number of buys
- 99
- Number of sells
- 50
Quarterly Holders Quick Answers
What is CUSIP 30233G209?
CUSIP 30233G209 identifies EYPT - EyePoint, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 30233G209:
Top shareholders of EYPT - EyePoint, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP |
3/4/5
13D/G
13F
|
Former 10% Owner · Company |
10%
from 13D/G
|
8,265,000
|
$129,793,560 | -$942,240 | 04 Dec 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
7.5%
|
6,192,715
|
$88,184,262 | — | 30 Sep 2025 | |
| EW Healthcare Partners, L.P. |
3/4/5
|
Other*, 10%+ Owner |
—
class O/S missing
|
3,490,921
|
$87,327,483 | — | 01 Sep 2023 | |
| Adage Capital Management, L.P. |
13D/G
3/4/5
|
10%+ Owner |
5.7%
|
4,700,000
|
$81,921,000 | -$14,986,000 | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
6.8%
|
5,559,782
|
$79,171,296 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.5%
from 13D/G
|
4,964,526
|
$70,694,849 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
13D/G
|
Company |
6.7%
from 13D/G
|
4,416,332
|
$62,888,567 | — | 30 Sep 2025 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
4.3%
|
3,572,335
|
$62,265,799 | $0 | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
4,171,884
|
$59,407,621 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.6%
|
3,794,516
|
$54,033,908 | — | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
4.3%
|
3,572,335
|
$50,870,050 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.6%
|
2,135,389
|
$30,407,939 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.4%
|
2,005,365
|
$28,556,398 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.2%
|
1,796,000
|
$25,575,040 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,524,526
|
$21,714,141 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.8%
|
1,514,606
|
$21,567,990 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
1,473,199
|
$20,978,354 | — | 30 Sep 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
— |
4.7%
|
3,181,818
|
$20,809,090 | $0 | 31 Dec 2024 | |
| Essex Woodlands Management, Inc. |
13F
|
Company |
1.3%
|
1,084,857
|
$15,448,362 | — | 30 Sep 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.3%
|
1,050,000
|
$14,952,000 | — | 30 Sep 2025 | |
| Patient Square Capital LP |
13F
|
Company |
1.2%
|
1,011,839
|
$14,408,587 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.2%
|
1,010,331
|
$14,387,118 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.2%
|
978,129
|
$13,928,557 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.97%
|
796,802
|
$11,346,460 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.92%
|
756,087
|
$10,766,679 | — | 30 Sep 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.87%
|
716,453
|
$10,209,953 | — | 30 Sep 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.79%
|
650,000
|
$9,256,000 | — | 30 Sep 2025 | |
| Artia Global Partners LP |
13F
|
Company |
0.76%
|
628,367
|
$8,947,946 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.65%
|
531,723
|
$7,571,736 | — | 30 Sep 2025 | |
| Principia Wealth Advisory, LLC |
13F
|
Company |
0.65%
|
530,725
|
$7,557,524 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.61%
|
504,053
|
$7,177,715 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.59%
|
483,054
|
$6,878,689 | — | 30 Sep 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.45%
|
367,594
|
$5,234,539 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.43%
|
355,810
|
$5,066,734 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.43%
|
350,164
|
$4,986,336 | — | 30 Sep 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.42%
|
347,892
|
$4,953,982 | — | 30 Sep 2025 | |
| MYDA Advisors LLC |
13F
|
Company |
0.36%
|
300,000
|
$4,272,000 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.35%
|
290,818
|
$4,141,248 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.31%
|
258,783
|
$3,685,000 | — | 30 Sep 2025 | |
| Bleichroeder LP |
13F
|
Company |
0.31%
|
256,515
|
$3,652,774 | — | 30 Sep 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.3%
|
247,754
|
$3,480,944 | — | 30 Sep 2025 | |
| AXA Investment Managers S.A. |
13F
|
Company |
0.3%
|
244,427
|
$3,480,640 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
230,837
|
$3,287,119 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.28%
|
229,087
|
$3,261,125 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.26%
|
215,450
|
$3,068,008 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
211,897
|
$3,017,409 | — | 30 Sep 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.24%
|
201,348
|
$2,867,196 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.22%
|
179,436
|
$2,555,169 | — | 30 Sep 2025 | |
| Therapeutics Ocumension |
3/4/5
|
Director |
—
class O/S missing
|
100,221
|
$2,507,088 | — | 11 Jan 2024 | |
| Ye Liu |
3/4/5
|
Director |
—
class O/S missing
|
100,221
|
$2,507,088 | — | 11 Jan 2024 |
Institutional Holders of EyePoint, Inc. - Common Stock (EYPT) as of Q4 2025
As of 31 Dec 2025,
EyePoint, Inc. - Common Stock (EYPT) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
83,462,300 shares.
The largest 10 holders included
Cormorant Asset Management, LP, SUVRETTA CAPITAL MANAGEMENT, LLC, BlackRock, Inc., FEDERATED HERMES, INC., FRANKLIN RESOURCES INC, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., Paradigm Biocapital Advisors LP, TCG Crossover Management, LLC, and JANUS HENDERSON GROUP PLC.
This page lists
164
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
148
Q4 2025 holders
164
Holder diff
16
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.